MIC Capital Management UK LLP
MIC Capital Management UK LLP is an SEC-registered investment adviser based in London, United Kingdom that reports managing 1 hedge fund on Form ADV. It reports $36.8 billion in regulatory assets under management. Its private funds, of all types, hold $23.1 billion in gross assets. Its disclosed U.S. stock holdings returned an estimated +8.0% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +6.4% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- $36.8 billionForm ADV Item 5.F
- Gross assets of private funds
- $23.1 billionAll private fund types, Form ADV
- Hedge funds managed
- 135 private funds in total
- Employees
- 236Form ADV Item 5.A
- Registration
- SEC-registered adviserCRD 316617
- Latest Form ADV
- 07/15/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +33.8% | +14.8% |
| Q1 2026 | -19.3% | -4.6% |
| Q4 2025 | -7.0% | +2.4% |
| Q3 2025 | +27.3% | +7.8% |
| Q2 2025 | +6.6% | +10.4% |
| Q1 2025 | -28.3% | -4.5% |
| Q4 2024 | +0.8% | +2.1% |
| Q3 2024 | +8.0% | +5.4% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.
13F holdings as of Sep 30, 2026
All 13 share positions ($463,386,482) reported by MIC Capital Management UK LLP on Form 13F for the quarter ended Sep 30, 2026, filed Nov 13, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.
Share of the reported 13F portfolio, ten largest positions
- Blue Owl Technology Fin Corp63.06%
- Hayward Hldgs Inc14.13%
- Recursion Pharmaceuticals In7.36%
- Electra Therapeutics Inc4.80%
- Klarna Group PLC2.28%
- Ssga Active TR2.13%
- Ssga Active TR2.08%
- Capital One Finl Corp2.00%
- Archer Aviation Inc0.75%
- Neumora Therapeutics Inc.0.57%
| Stock | Value | % of 13F portfolio | Shares | Shares vs prior quarter |
|---|---|---|---|---|
| Blue Owl Technology Fin Corp | $292,218,357 | 63.06% | 29,787,804 | New |
| Hayward Hldgs Inc | $65,494,686 | 14.13% | 5,350,873 | -13.30% |
| Recursion Pharmaceuticals In | $34,093,745 | 7.36% | 8,255,144 | -14.40% |
| Electra Therapeutics Inc | $22,243,163 | 4.80% | 1,977,170 | New |
| Klarna Group PLC | $10,562,450 | 2.28% | 852,498 | Unchanged |
| Ssga Active TR | $9,856,109 | 2.13% | 399,680 | New |
| Ssga Active TR | $9,654,752 | 2.08% | 401,445 | New |
| Capital One Finl Corp | $9,269,484 | 2.00% | 48,011 | Unchanged |
| Archer Aviation Inc | $3,479,000 | 0.75% | 700,000 | Unchanged |
| Neumora Therapeutics Inc. | $2,659,469 | 0.57% | 4,460,700 | Unchanged |
| Rocket Lab Corp | $2,482,559 | 0.54% | 35,628 | Unchanged |
| Lyell Immunopharma Inc | $852,004 | 0.18% | 87,028 | Unchanged |
| Billiontoone Inc | $520,704 | 0.11% | 4,892 | Unchanged |
Changes since Jun 30, 2026
Comparing the share counts in the two quarter-end filings: 4 new positions, 7 sold out, 0 increased, 2 reduced and 7 unchanged.
Number of positions (a count, not dollars)
- New positions4
- Increased0
- Unchanged7
- Reduced2
- Sold out7
New positions
| Stock | Value | Shares |
|---|---|---|
| Blue Owl Technology Fin Corp | $292,218,357 | 29,787,804 |
| Electra Therapeutics Inc | $22,243,163 | 1,977,170 |
| Ssga Active TR | $9,856,109 | 399,680 |
| Ssga Active TR | $9,654,752 | 401,445 |
Sold out
| Stock | Value at Jun 30, 2026 | Shares held then |
|---|---|---|
| Revolution Medicines Inc | $99,582,956 | 531,733 |
| Restaurant Brands Intl Inc | $28,003,580 | 386,203 |
| Coupang Inc | $24,542,872 | 1,412,946 |
| Grab Holdings Limited | $18,850,000 | 5,000,000 |
| Meta Platforms Inc | $18,757,557 | 33,300 |
| Alibaba Group Hldg LTD | $14,397,000 | 150,000 |
| Monday Com LTD | $4,777,740 | 66,000 |
Largest reductions
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Hayward Hldgs Inc | -820,654 | -13.30% | $65,494,686 | 5,350,873 |
| Recursion Pharmaceuticals In | -1,388,889 | -14.40% | $34,093,745 | 8,255,144 |
Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.
From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures
Private funds reported on Form ADV (20)
As reported in the adviser's Form ADV filed Mar 29, 2024. Funds also listed from Form D are shown above.
Fund vehicles: feeder funds and single-deal vehicles (10)
Feeder funds invest through a master fund; single-deal vehicles (SPVs, co-investments, series) hold one investment.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures